دورية أكاديمية
Emerging drugs for the treatment of herpetic keratitis.
| العنوان: | Emerging drugs for the treatment of herpetic keratitis. |
|---|---|
| المؤلفون: | Kapoor D; Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL, USA.; Department of Ophthalmology and Visual Sciences, University of Illinois Medical Center, Chicago, IL, USA., Sharma P; Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL, USA., Shukla D; Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL, USA.; Department of Ophthalmology and Visual Sciences, University of Illinois Medical Center, Chicago, IL, USA. |
| المصدر: | Expert opinion on emerging drugs [Expert Opin Emerg Drugs] 2024 Jun; Vol. 29 (2), pp. 113-126. Date of Electronic Publication: 2024 Apr 11. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101135662 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7623 (Electronic) Linking ISSN: 14728214 NLM ISO Abbreviation: Expert Opin Emerg Drugs Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London, UK : Ashley Publications Ltd. |
| مواضيع طبية MeSH: | Keratitis, Herpetic*/drug therapy , Keratitis, Herpetic*/virology , Antiviral Agents*/pharmacology , Antiviral Agents*/therapeutic use , Herpesvirus 1, Human*/drug effects , Herpesvirus 1, Human*/isolation & purification , Drug Development*, Humans ; Animals ; Drug Resistance, Viral ; Drug Design |
| مستخلص: | Introduction: Herpes simplex keratitis stands as a prominent factor contributing to infectious blindness among developed nations. On a global scale, over 60% of the population tests positive for herpes simplex virus type-1 (HSV-1). Despite these statistics, there is currently no vaccine available for the virus. Moreover, the conventional nucleoside drugs prescribed to patients are proving ineffective in addressing issues related to drug resistance, recurrence, latency, and the escalating risk of vision loss. Hence, it is imperative to continually explore all potential avenues to restrict the virus. This review article centers on the present treatment methods for HSV-1 keratitis (HSK), highlighting the ongoing clinical trials. It delves into the emerging drugs, their mode-of-action and future therapeutics. Areas Covered: The review focuses on the significance of a variety of small molecules targeting HSV-1 lifecycle at multiple steps. Peer-reviewed articles and abstracts were searched in MEDLINE, PubMed, Embase, and clinical trial websites. Expert Opinion: The exploration of small molecules that target specific pathways within the herpes lifecycle holds the potential for substantial impact on the antiviral pharmaceutical market. Simultaneously, the pursuit of disease-specific biomarkers has the capacity to usher in a transformative era in diagnostics within the field. |
| فهرسة مساهمة: | Keywords: Herpes Simplex Keratitis (HSK); diagnostics; herpes simplex virus-1 (HSV-1); ocular disease; therapeutics |
| المشرفين على المادة: | 0 (Antiviral Agents) |
| تواريخ الأحداث: | Date Created: 20240411 Date Completed: 20240621 Latest Revision: 20240627 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1080/14728214.2024.2339899 |
| PMID: | 38603466 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-7623 |
|---|---|
| DOI: | 10.1080/14728214.2024.2339899 |